AbbVie (NYSE:ABBV) Price Target Raised to $265.00 at Canaccord Genuity Group

AbbVie (NYSE:ABBV) had its price target boosted by Canaccord Genuity Group from $262.00 to $265.00 in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

ABBV has been the topic of several other research reports. Citigroup cut their price objective on AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a report on Tuesday, January 27th. Barclays assumed coverage on AbbVie in a report on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price objective on the stock. Morgan Stanley boosted their price objective on AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a report on Thursday. Piper Sandler cut their price objective on AbbVie from $299.00 to $294.00 and set an “overweight” rating on the stock in a report on Thursday, April 23rd. Finally, Evercore cut their price objective on AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a report on Wednesday, February 4th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $252.90.

AbbVie Stock Up 3.8%

NYSE:ABBV opened at $211.66 on Thursday. AbbVie has a 52 week low of $176.57 and a 52 week high of $244.81. The company has a market capitalization of $374.26 billion, a P/E ratio of 104.27, a P/E/G ratio of 0.73 and a beta of 0.38. The stock’s fifty day moving average is $214.55 and its two-hundred day moving average is $221.60.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. The company had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a negative return on equity of 911.57% and a net margin of 5.79%.The company’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.46 earnings per share. Sell-side analysts anticipate that AbbVie will post 14.13 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s payout ratio is presently 293.22%.

Insider Buying and Selling at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares of the company’s stock, valued at $8,771,510. The trade was a 36.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.06% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Chelsea Counsel Co. acquired a new position in shares of AbbVie during the 3rd quarter worth about $26,000. Litman Gregory Wealth Management LLC acquired a new position in shares of AbbVie during the 4th quarter worth about $28,000. Westend Capital Management LLC acquired a new position in shares of AbbVie during the 4th quarter worth about $29,000. Imprint Wealth LLC boosted its position in shares of AbbVie by 56.3% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after acquiring an additional 45 shares in the last quarter. Finally, Texas Capital Bancshares Inc TX acquired a new position in shares of AbbVie during the 3rd quarter worth about $31,000. 70.23% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Multiple sell‑side upgrades and price‑target increases (Bank of America upgraded ABBV to Buy and lifted its PT to $234), signaling renewed analyst conviction around Skyrizi/Rinvoq growth and easing concerns about competitive erosion. Bank of America Upgrades AbbVie
• Positive Sentiment: Additional bullish price‑target moves from major firms — Morgan Stanley raised its PT to $278 (overweight) and Canaccord boosted its PT to $265 — adding upside runway and institutional support for the stock. Canaccord / Morgan Stanley Coverage
• Positive Sentiment: Q1 results and outlook: AbbVie reported ~ $15B revenue in Q1 with strong Skyrizi and Rinvoq sales and raised 2026 adjusted EPS guidance, which underpins the bullish analyst reactions and helps offset Humira declines. AbbVie tops quarterly expectations
• Neutral Sentiment: Corporate PR / ecosystem activity — AbbVie awarded the AbbVie Biotech Innovators Award to RIME Therapeutics (lab space, mentorship) in Canada, boosting long‑term innovation positioning but with limited near‑term financial impact. AbbVie and adMare Announce RIME Therapeutics Award
• Neutral Sentiment: Allergan Aesthetics launched a charitable marketing initiative tied to its Allē program — positive PR and modest commercial support for aesthetics segment but not material for near‑term earnings. Allergan Aesthetics Philanthropy
• Negative Sentiment: Mixed/nuanced earnings signals: while revenue beat and guidance was raised, some metrics and accounting items pulled adjusted EPS dynamics lower in pockets (some data feeds flagged EPS misses or small estimate revisions), creating short‑term volatility. Coverage of earnings nuance
• Negative Sentiment: Minor analyst cuts and insider/positioning signals: Erste trimmed some FY estimates slightly and Quiver summaries show recent insider sales and mixed institutional flows — items investors watch as potential near‑term headwinds. Erste / Institutional Notes

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.